vs

Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $105.5M, roughly 2.0× CARRIAGE SERVICES INC). CARRIAGE SERVICES INC runs the higher net margin — 11.6% vs -62.0%, a 73.7% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 8.0%). CARRIAGE SERVICES INC produced more free cash flow last quarter ($6.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 1.0%).

Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

CSV vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
2.0× larger
RARE
$207.3M
$105.5M
CSV
Growing faster (revenue YoY)
RARE
RARE
+17.9% gap
RARE
25.9%
8.0%
CSV
Higher net margin
CSV
CSV
73.7% more per $
CSV
11.6%
-62.0%
RARE
More free cash flow
CSV
CSV
$107.0M more FCF
CSV
$6.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
1.0%
CSV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSV
CSV
RARE
RARE
Revenue
$105.5M
$207.3M
Net Profit
$12.3M
$-128.6M
Gross Margin
34.8%
Operating Margin
23.3%
-54.7%
Net Margin
11.6%
-62.0%
Revenue YoY
8.0%
25.9%
Net Profit YoY
24.5%
3.5%
EPS (diluted)
$0.76
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSV
CSV
RARE
RARE
Q4 25
$105.5M
$207.3M
Q3 25
$102.7M
$159.9M
Q2 25
$102.1M
$166.5M
Q1 25
$107.1M
$139.3M
Q4 24
$97.7M
$164.6M
Q3 24
$100.7M
$139.5M
Q2 24
$102.3M
$147.0M
Q1 24
$103.5M
$108.8M
Net Profit
CSV
CSV
RARE
RARE
Q4 25
$12.3M
$-128.6M
Q3 25
$6.6M
$-180.4M
Q2 25
$11.7M
$-115.0M
Q1 25
$20.9M
$-151.1M
Q4 24
$9.9M
$-133.2M
Q3 24
$9.9M
$-133.5M
Q2 24
$6.3M
$-131.6M
Q1 24
$7.0M
$-170.7M
Gross Margin
CSV
CSV
RARE
RARE
Q4 25
34.8%
Q3 25
35.3%
Q2 25
35.2%
Q1 25
35.3%
Q4 24
34.4%
Q3 24
35.2%
Q2 24
36.2%
Q1 24
36.0%
Operating Margin
CSV
CSV
RARE
RARE
Q4 25
23.3%
-54.7%
Q3 25
17.0%
-106.9%
Q2 25
23.5%
-64.8%
Q1 25
29.5%
-102.6%
Q4 24
21.6%
-74.3%
Q3 24
22.7%
-94.6%
Q2 24
18.0%
-79.1%
Q1 24
18.8%
-151.9%
Net Margin
CSV
CSV
RARE
RARE
Q4 25
11.6%
-62.0%
Q3 25
6.4%
-112.8%
Q2 25
11.5%
-69.0%
Q1 25
19.5%
-108.5%
Q4 24
10.1%
-80.9%
Q3 24
9.8%
-95.7%
Q2 24
6.1%
-89.5%
Q1 24
6.7%
-156.8%
EPS (diluted)
CSV
CSV
RARE
RARE
Q4 25
$0.76
$-1.28
Q3 25
$0.41
$-1.81
Q2 25
$0.74
$-1.17
Q1 25
$1.34
$-1.57
Q4 24
$0.62
$-1.34
Q3 24
$0.63
$-1.40
Q2 24
$0.40
$-1.52
Q1 24
$0.45
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSV
CSV
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$1.7M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$254.8M
$-80.0M
Total Assets
$1.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSV
CSV
RARE
RARE
Q4 25
$1.7M
$421.0M
Q3 25
$1.2M
$202.5M
Q2 25
$1.4M
$176.3M
Q1 25
$4.6M
$127.1M
Q4 24
$1.2M
$174.0M
Q3 24
$1.3M
$150.6M
Q2 24
$1.5M
$480.7M
Q1 24
$1.7M
$112.3M
Stockholders' Equity
CSV
CSV
RARE
RARE
Q4 25
$254.8M
$-80.0M
Q3 25
$242.1M
$9.2M
Q2 25
$235.4M
$151.3M
Q1 25
$223.1M
$144.2M
Q4 24
$208.6M
$255.0M
Q3 24
$198.1M
$346.8M
Q2 24
$187.9M
$432.4M
Q1 24
$179.6M
$140.3M
Total Assets
CSV
CSV
RARE
RARE
Q4 25
$1.3B
$1.5B
Q3 25
$1.3B
$1.2B
Q2 25
$1.3B
$1.3B
Q1 25
$1.3B
$1.3B
Q4 24
$1.3B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.3B
$1.6B
Q1 24
$1.3B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSV
CSV
RARE
RARE
Operating Cash FlowLast quarter
$14.1M
$-99.8M
Free Cash FlowOCF − Capex
$6.2M
$-100.8M
FCF MarginFCF / Revenue
5.9%
-48.6%
Capex IntensityCapex / Revenue
7.5%
0.5%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$40.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSV
CSV
RARE
RARE
Q4 25
$14.1M
$-99.8M
Q3 25
$24.7M
$-91.4M
Q2 25
$8.1M
$-108.3M
Q1 25
$13.8M
$-166.5M
Q4 24
$9.3M
$-79.3M
Q3 24
$20.9M
$-67.0M
Q2 24
$2.2M
$-77.0M
Q1 24
$19.7M
$-190.7M
Free Cash Flow
CSV
CSV
RARE
RARE
Q4 25
$6.2M
$-100.8M
Q3 25
$18.0M
$-92.7M
Q2 25
$5.2M
$-110.7M
Q1 25
$10.6M
$-167.8M
Q4 24
$4.9M
$-79.5M
Q3 24
$16.2M
$-68.6M
Q2 24
$-1.4M
$-79.0M
Q1 24
$16.2M
$-193.9M
FCF Margin
CSV
CSV
RARE
RARE
Q4 25
5.9%
-48.6%
Q3 25
17.5%
-58.0%
Q2 25
5.1%
-66.5%
Q1 25
9.9%
-120.5%
Q4 24
5.0%
-48.3%
Q3 24
16.1%
-49.2%
Q2 24
-1.4%
-53.7%
Q1 24
15.6%
-178.2%
Capex Intensity
CSV
CSV
RARE
RARE
Q4 25
7.5%
0.5%
Q3 25
6.5%
0.8%
Q2 25
2.8%
1.5%
Q1 25
3.0%
1.0%
Q4 24
4.5%
0.1%
Q3 24
4.6%
1.2%
Q2 24
3.5%
1.4%
Q1 24
3.4%
3.0%
Cash Conversion
CSV
CSV
RARE
RARE
Q4 25
1.15×
Q3 25
3.76×
Q2 25
0.69×
Q1 25
0.66×
Q4 24
0.94×
Q3 24
2.11×
Q2 24
0.34×
Q1 24
2.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSV
CSV

Propertyand Merchandise$47.8M45%
Cemetery Interment Rights$24.8M23%
Merchandise$18.9M18%
Other Revenue$10.2M10%
Other$3.9M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons